Paxlovid, other COVID-fighting medications more cost-effective than hospitalizations, Montreal study finds
Shortly after Health Canada green-lit the COVID-treating drug Paxlovid, researchers from the Research Institute of the McGill University Health Centre published a study comparing the efficacy and costs of various medications used to combat the virus, including this new addition from Pfizer.
The study found that use of Paxlovid and some other treatments is more cost effective than hospitalization and could reduce the strain on the health network.
Numerous drugs have been repurposed to treat COVID-19 since the pandemic began, from the antidepressant ‘fluvoxamine’ to the gout treatment ‘colchicine.’ But Paxlovid is the first at-home drug designed specifically for the virus to hit the market in Canada. The antiviral medication is prescribed and taken orally, making it a promising treatment against mild-to-moderate cases.
Senior author of the study Dr. Emily McDonald said in a press release that the aim of the research is to help medical professionals determine the most effective and cost efficient approaches to managing COVID-19.
“Available drugs, whether repurposed or new, differ in efficacy, toxicity, cost and complexity of administration. We felt it was important to conduct this study to facilitate comparative decision-making regarding treatment choice,” she said.
The study was published Wednesday in the Oxford journal Open Forum Infectious Diseases.
MONEY SAVERS
When measuring the cost of the drug versus its ability to prevent hospitalization, the study found that Paxlovid, fluvoxamine, colchicine, and inhaled corticosteroids are below the estimated hospitalization cost, which averages at $21,752 per admission.
Paxlovid (Nirmatrelvir-Ritonavir)
Researchers found that Paxlovid is most effective in preventing hospitalizations.
- Prevented hospitalizations: One out of every 24 patients
- Cost per prevented hospitalization: $12,720
Health Canada says a prescription of the medication can be given to anyone over 18 who is at risk of becoming seriously ill from the virus.
Fluvoxamine
Fluvoxamine, on the other hand, averts far fewer hospitalizations but for a fraction of the cost.
- Prevented hospitalizations: One out of every 80 patients
- Cost per prevented hospitalization: $1,122
The drug is sold under the name Luvox and is commonly used to treat obsessive-compulsive disorder and depression.
In a clinical trial ouside from this particular study, some of the same McGill researchers are examining the effects of fluvoxamine more closely. However, Ontario is the only province so far to list the drug as a treatment to be considered for COVID-19 outside of clinical trials.
Colchicine
Colchicine, normally used for the treatment and prevention of gout flare ups, proved to be the least effective medication in the study in terms of reducing hospital admissions.
- Prevented hospitalizations: One out of every 91 patients
- Cost per prevented hospitalization: $3,333
In 2021, a controversial study from the Montreal Heart Institute suggested colchicine was a promising therapeutic approach for COVID-19 patients, but the results of the study and its methodology have since been widely contested.
Inhaled corticosteroids
Inhaled corticosteroids are normally used to treat asthma.
- Prevented hospitalizations: One out of every 72 patients
- Cost per prevented hospitalization: $9,475
PRICIER TREATMENTS
While other antiviral drugs prove to be nearly as effective in curbing hospitalizations as Paxlovid, according to the study, they are frequently more expensive and difficult to obtain.
Remdesivir
Remdesivir, which was originally used to treat Ebola, was approved for use by the Canadian government in July 2020.
- Prevented hospitalizations: One out of every 28 patients
- Cost per prevented hospitalization: $52,416
Sotrovimab
Sotrovimab has a similar success rate to Paxlovid but is far more expensive. The drug was approved for Canada in July 2021.
- Prevented hospitalizations: One of out every 25 patients
- Cost per prevented hospitalization: $52,500
Casirivimab-Imdevimab / Bamlanivimab-Etesevimab
The combination of antibodies casirivimab and imdevimab, as well as the combination of bamlanivimab and etesevimab, are the most expensive treatments on the list and produced the same results in the study.
- Prevented hospitalizations: One of out every 29 patients
- Cost per prevented hospitalization: $60,900
Health Canada okayed the use of casirivimab-imdevimab in June 2021, although the drug is not an effective treatment against the Omicron variant, according to its own manufacturer.
The use of bamlanivimab on its own was approved in Canada in November 2020, but combination of bamlanivimab and etesevimab has yet to be given the thumbs up.
Molnupiravir
Although not yet approved, the medication has been under review by Health Canada since August.
- Prevented hospitalizations: One out of every 50 patients
- Cost per prevented hospitalization: $35,000
EASING THE STRAIN
As Omicron surges across the province and hospitals overflow, drugs such as Paxlovid are looked to as a potential means of easing the burden.
The study authors say that to “prioritize deployment of therapies and capacity building,” health authorities are faced with important decisions regarding which treatments to implement.
“There is an ongoing need to identify effective treatments that can be administered early in the disease to prevent COVID-19 hospitalization and death and to make them available and accessible in all regions,” the study reads.
Quebec is set to receive 6,300 Paxlovid treatments in the near future, although Health Minister Christian Due points out that vaccination is still the province’s “best weapon.”
The province is expected to receive an additional 19,000 treatments in April.
CTVNews.ca Top Stories
Police arrest 3 Indian nationals in killing of B.C. Sikh activist Hardeep Singh Nijjar
Three people have been arrested and charged in the killing of B.C. Sikh activist Hardeep Singh Nijjar – as authorities continue investigating potential connections to the Indian government.
Five areas Canada's foreign interference commissioner says needs more investigation
Commissioner Marie-Josee Hogue released her interim report examining foreign election interference on Friday. Here are five elements of the issue that Hogue says she needs to further probe before she can make conclusions or recommendations.
Police officer hit by driver of fleeing vehicle in Toronto
York Regional Police say they are continuing to search for a suspect in an auto theft investigation who was captured on video running over a police officer in Toronto last month.
Why your airfare may be getting more expensive
Skyrocketing airfare prices are linked to heightened competition and rising food and fuel, according to the CAA.
TD worst-case scenario more likely after drug money laundering allegations: analyst
TD Bank Group could be hit with more severe penalties than previously expected, says a banking analyst after a report that the investigation it faces in the U.S. is tied to laundering illicit fentanyl profits.
New weight-loss drug Wegovy not a 'magic bullet,' doctor warns
As Wegovy becomes available to Canadians starting Monday, a medical expert is cautioning patients wanting to use the drug to lose weight that no medication is a ''magic bullet,' and the new medication is meant particularly for people who meet certain criteria related to obesity and weight.
Drew Carey is never quitting 'The Price Is Right'
Drew Carey took over as host of 'The Price Is Right' and hopes he’s there for life. 'I'm not going anywhere,' he told 'Entertainment Tonight' of the job he took over from longtime host Bob Barker in 2007.
Funeral today for broadcasting legend and voice of 'Hockey Night in Canada' Bob Cole
A funeral is being held today for hockey broadcasting legend Bob Cole in his hometown of St. John's, N.L.
Foreign meddling 'did not affect' overall federal election results: inquiry report
Foreign interference by China did not affect the overall results of the 2019 and 2021 general elections won by Justin Trudeau's Liberals, a federal commission of inquiry has found.